Kepler Cheuvreux upgraded Novo Nordisk (NVO) to Buy from Hold with a price target of DKK 630, down from DKK 715. The firm views the company’s weight loss opportunity as compelling following the stock’s recent selloff.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NVO:
- Giftify reports 916% w/w increase in pharmacy retailer gift cards sold
- Positive Outlook for Novo Nordisk: Strong Data, Expertise, and Next-Gen Developments Drive Buy Rating
- Roche hires Novo Nordisk executive amid obesity drug push, Bloomberg reports
- Novo Nordisk (NVO) Sinks after Weight-Loss Drug Trial Misses Expectations
- Novo Nordisk under pressure as obesity drug disappoints in diabetes trial